LB Pharmaceuticals Inc Common Stock (LBRX) vs Latigo Biotherapeutics Inc. (LTGO)

A side-by-side comparison of LB Pharmaceuticals Inc Common Stock and Latigo Biotherapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

LBRX

LB Pharmaceuticals Inc Common Stock

$978M

$34.12HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT

LTGO

Latigo Biotherapeutics Inc.

$993M

$16.51HealthcareDelayed quote: Oct 6, 2026, 10:39 AM EDT

Total return — LBRX vs LTGO

growth of $100 · dividends reinvested · last 1y

LBRX -28.1% (-28.1%/yr)LTGO -7.6% (-7.6%/yr)LTGO compounded faster over this window

LBRX LTGO

Metrics side by side

Total return (annualized)

Metric	LBRX	LTGO
Total return (1Y)	129.12%	N/A

LTGO is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full LBRX analysis Full LTGO analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.